NCT03327571
- Conditions
- Classical Hodgkin Lymphoma, Disease Attributes, Pathologic Processes, +3 more
- Locations
-
- Pusan National University Hospital Busan, South Korea
Clinical trial condition
Classical Hodgkin Lymphoma
Explore clinical trials studying Classical Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.
42 public trials
10 recruiting studies
Classical Hodgkin Lymphoma trial results
NCT02414568
- Conditions
- Classical Hodgkin Lymphoma
- Locations
-
- A. Z. Sint-Jan Bruges, Belgium
- Clinique Universitaire St Luc Brussels, Belgium
- CHU de Liège Liège, Belgium
- UCL Mont Godinne Yvoir, Belgium
NCT02243436
- Conditions
- Classical Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +7 more
- Locations
-
- Hospital Son Espases Palma, Balearic Islands, Spain
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
- Institut Català d'Oncologia, Hospital Duran i Reynals L'Hospitalet de Llobregat, Barcelona, Spain
- Hospital Universitario Central de Asturias Oviedo, Principality of Asturias, Spain
NCT00305149
- Conditions
- Classical Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
- Locations
-
- Eldad Dann Haifa, Israel
Active, Not Recruiting
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Chronic Disease, +37 more
- Locations
-
- Colorado Blood Cancer Network Denver, Colorado, United States
- University of Maryland, Greenbaum Comprehensive Cancer Center Baltimore, Maryland, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- START - Midwest Grand Rapids, Michigan, United States
Active, Not Recruiting
Itacitinib + Everolimus in Hodgkin Lymphoma
NCT03697408
- Conditions
- Classical Hodgkin Lymphoma
- Locations
-
- Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
NCT05404945
- Conditions
- Classical Hodgkin Lymphoma
- Locations
-
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
- University of Pennsylvania Philadelphia, Pennsylvania, United States
- University of Virginia Charlottesville, Virginia, United States
Active, Not Recruiting
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02940301
- Conditions
- Classical Hodgkin Lymphoma
- Locations
-
- Winship Cancer Center of Emory University Atlanta, Georgia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
NCT04067037
- Conditions
- Classical Hodgkin Lymphoma
- Locations
-
- An Yang Tumor Hospital Anyang, Henan, China
- The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology Luoyang, Henan, China
- Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Zhengzhou, Henan, China
Active, Not Recruiting
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
NCT03480334
- Conditions
- Classical Hodgkin Lymphoma
- Locations
-
- 1st Department of Medicine, Cologne University Hospital Cologne, Germany